Talazoparib for small cell lung cancer

Talazoparib (Talazoparib) is a PARP (Polymerase Single Nucleotide Defect Repair Enzyme) inhibitor that is currently in its labeling and has not been approved for the treatment of small cell lung cancer. Small cell lung cancer is usually treated with a combination of chemotherapy, radiotherapy and surgery. The combination of talazopanib and temozolomide resulted in an objective response rate (ORR) of 39.3% in patients with extensive-stage small cell lung cancer (ES-SCLC) who relapsed or were refractory to first-line platinum-based chemotherapy, according to data from the Phase 22 UCLA/TRIO-US L-07 trial.

In previous models of this disease, tazopanib was found to have cytotoxic effects by inhibitingPARP protein 1/2 and trapping PARP on DNA, as temozolomide enhances anti-tumor responses by promoting genomic instability. Regarding safety, the most common hematological adverse reactions of combination therapy include anemia, decreased neutrophil count, decreased platelet count, and decreased white blood cell count, and the most common non-hematological adverse reactions are fatigue, diarrhea, and nausea.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).